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Introduction
Tumor cells acquire nonsynonymous mutations during tumorigenesis (1). Some nonsynonymous muta-
tions, denoted as neoantigens, can trigger T cell activation via T cell receptor (TCR) engagement with 
MHC molecules (HLA, in human) presenting the peptide containing the mutated amino acid (pHLA) 
on target cells (2). Recently, we showed in 101 metastatic melanoma patients that reinfusing autologous 
tumor-infiltrating lymphocytes (TILs) could mediate a durable complete response (CR) rate and overall 
response rate (ORR) of  24% and 56%, respectively (3). Furthermore, adoptive cell transfer (ACT) treat-
ment with selected TILs targeting neoantigens caused significant tumor regression in a small percentage of  
metastatic epithelial cancer patients (4–6). One potential explanation for this low response is that the T cells 
used for treatment contained a low frequency of  tumor-reactive T cells, which may be a consequence of  
the overgrowth of  nonreactive cells during extensive in vitro culturing of  T cells that is required to generate 
sufficient T cell numbers for patient treatment. Due to persistent antigen exposure in the tumor microenvi-
ronment, TILs often present exhaustion hallmarks and therefore their growth in vitro can be limited (7). In 
addition, due to intratumoral heterogeneity, neoantigens targeted by ACT can be expressed subclonally in 
the tumor, resulting in tumor escape (8, 9). To address these issues, we are planning a new clinical trial in 
which we retrovirally transduce autologous peripheral blood mononuclear cells (PBMCs) with neoantigen-
reactive TCRs isolated from the patient (NCT03412877). Targeting multiple neoantigens or shared onco-
genes may increase our chances of  attacking multiple clones of  the tumor.
Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TILs) targeting neoantigens 
can mediate tumor regression in selected patients with metastatic epithelial cancer. However, 
effectively identifying and harnessing neoantigen-reactive T cells for patient treatment remains 
a challenge and it is unknown whether current methods to detect neoantigen-reactive T cells are 
missing potentially clinically relevant neoantigen reactivities. We thus investigated whether the 
detection of neoantigen-reactive TILs could be enhanced by enriching T cells that express PD-1 and/
or T cell activation markers followed by microwell culturing to avoid overgrowth of nonreactive 
T cells. In 6 patients with metastatic epithelial cancer, this method led to the detection of CD4+ 
and CD8+ T cells targeting 18 and 1 neoantigens, respectively, compared with 6 and 2 neoantigens 
recognized by CD4+ and CD8+ T cells, respectively, when using our standard TIL fragment screening 
approach. In 2 patients, no recognition of mutated peptides was observed using our conventional 
screen, while our high-throughput approach led to the identification of 5 neoantigen-reactive T 
cell receptors (TCRs) against 5 different mutations from one patient and a highly potent MHC class 
II–restricted KRASG12V-reactive TCR from a second patient. In addition, in a metastatic tumor sample 
from a patient with serous ovarian cancer, we isolated 3 MHC class II–restricted TCRs targeting the 
TP53G245S hot-spot mutation. In conclusion, this approach provides a highly sensitive platform to 
isolate clinically relevant neoantigen-reactive T cells or their TCRs for cancer treatment.
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To select TILs for treatment as part of  clinical trial NCT01174121, we cut excised tumor(s) into 1- to 
2-mm3 fragments, cultured them ex vivo in high-dose IL-2, and tested the TILs from the fragments for 
reactivity against neoantigens using peptides or tandem minigenes (TMGs) encompassing the mutations 
identified in the tumor. TIL cultures that contain reactive T cells are further expanded and reinfused to the 
patient (10, 11). Although several techniques to enrich for reactive T cells have been developed (12–18), the 
detection of  tumor- or neoantigen-reactive T cells is still challenging. In a number of  these methods, T cells 
are enriched based on surface marker expression and further expanded and tested (15, 16, 18–20). Gros 
et al. and others showed that sorting TILs expressing programmed cell death protein 1 (PD-1) enriched 
tumor- and neoantigen-reactive T cells in patients with melanoma. However, several studies showed that 
terminally differentiated effector memory cells (Temra) express low levels of  PD-1 on their cell surface (21, 
22), although these cells were chronically exposed to antigen and may be clinically relevant (23). CD137, a 
costimulatory T cell protein, was also suggested as a candidate for reactive T cell enrichment; nevertheless, 
while CD137 is expressed on activated CD8+ cells it may not be reliable, as a sole marker, for the enrich-
ment of  activated CD4+ cells (15, 24). Importantly, in these enrichment approaches, the cells are expanded 
as mixed cultures that could lead to overgrowth by younger, potentially nonreactive cells, thereby diluting 
the reactive, exhausted cells in the culture (13, 16–18). An additional method isolated T cells from tumor 
and blood using pHLA tetramers, but this method was restricted to CD8+ cells and relied on predictions of  
peptide-HLA binding (12).
In the present study, we developed a nonbiased, 2-step, high-throughput limiting-dilution approach for 
detection and isolation of  neoantigen-reactive T cells that can potentially overcome some of  the problems 
discussed above. This approach enabled the enhanced detection of  neoantigen-reactive TILs in metastatic 
nonmelanoma tumor samples and the rapid isolation of  neoantigen-reactive TCRs for potential use in 
clinical trials. In this method, we FACS isolated TILs that expressed T cell costimulatory markers (CD134 
or CD137) and/or PD-1. We reasoned that the use of  both markers would enhance the enrichment of  
neoantigen-reactive CD4+ cells that would otherwise be missed by enriching TILs using CD137 alone and 
Temra cells that express low levels of  PD-1. Sorted cells underwent limiting-dilution cloning and were then 
expanded in microwell plates to avoid overgrowth of  nonreactive young cells at the expense of  exhausted 
reactive cells. Cultures that grew were tested against 25mer peptides encompassing mutations that were 
present in patient tumors. Employing this approach enabled us to detect 19 neoantigen T cell reactivities 
in 6 epithelial cancer samples. Moreover, CD4+ T cells reactive against KRASG12V and TP53G245S hot-spot 
mutations were isolated from 2 patients. Notably, reactive cultures were highly oligoclonal or clonal, which 
allowed us to efficiently sequence reactive TCRs using single-cell PCR (scPCR). This strategy provides a 
sensitive approach for the enhanced detection of  neoantigen-reactive TILs and can be utilized for the rapid 
identification of  neoantigen-reactive TCRs, which can be used to generate a personalized, neoantigen-
targeted TCR-gene therapy for patients with cancer.
Results
Developing a high-throughput TIL microwell culture method to detect and isolate neoantigen-reactive TCRs. The scheme 
we used to isolate neoantigen-reactive TILs is shown in Figure 1. Metastatic lesions were excised from cancer 
patients, enzymatically digested to obtain a single-cell suspension, and incubated overnight in T cell medium 
without cytokines. Cells were then stained and T cells were FACS isolated based on the expression of  PD-1 
and/or T cell activation markers (single positives and double positive, Figure 1). Enriched cells were cultured 
at low concentration in rapid expansion protocol (REP) conditions in the presence of  irradiated allogeneic 
feeder cells, IL-2, and OKT3 antibody, as described in detail in the Methods (Figure 1). Three to 4 weeks 
later, neoantigen reactivity of  the expanded cells was tested based on IFN-γ secretion and expression of  T cell 
activation markers after coculture with autologous antigen-presenting cells (APCs) expressing the patient’s 
own neoantigens as described in the Methods. Briefly, to decrease the number of  microcultures screened, cells 
from 2 cultures that grew were combined and cocultured with patient’s DCs pulsed with 2 pools of  25mer 
peptides containing the nonsynonymous mutations expressed in the patient’s tumor flanked by 12 amino 
acids of  the wild-type (WT) protein (Figure 1 and ref. 25). Cultures that showed specific reactivity against 
the pools, defined by 2-fold higher IFN-γ secretion or upregulation of  activation markers compared with the 
negative controls, were further expanded for testing (Figure 1). Additionally, cells from coculture wells that 
showed reactivity against peptide pools in IFN-γ ELISPOT assays were collected, stained, and FACS isolated 
based on activation markers in 96-well plates for single-cell TCR sequencing (Figure 1).
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Enhanced detection and isolation of  neoantigen-reactive TILs in metastatic epithelial tumors. To test the feasibility 
and sensitivity of our high-throughput culturing approach to detect neoantigen-reactive TILs, we studied a met-
astatic lesion from the adrenal gland in a patient with metastatic gastroesophageal junction adenocarcinoma 
(Pt.4078). This patient was enrolled in the NCT01174121 study for possible treatment using ACT with neoanti-
gen-reactive TILs. Neoantigen-reactive T cells were not detected in TILs when tumor fragments were screened 
using our standard method (Supplemental Figure 1A; supplemental material available online with this article; 
Figure 1. Illustration of the new high-throughput 
approach for enrichment, culturing, and screening 
strategy of TILs. (1) Tumor cell digests were thawed 
and rested overnight in complete media in the absence 
of exogenous cytokines. (2a) A piece of the tumor 
underwent whole-exome sequencing (WES) and RNA 
sequencing to identify nonsynonymous mutations. 
Based on mutation calls, 25mer peptides encompass-
ing the mutations at position 13 were synthesized. 
(2b) Cells were washed, labeled, and sorted based 
on PD-1 and/or activation markers (CD134 or CD137) 
expression (pink area represents that gate used in the 
sort). (3) Sorted cells were cultured in 96-well plates 
at 3 cells/well in the presence of irradiated allogeneic 
feeder cells, 3,000 IU/ml IL-2, and anti-CD3ε (OKT3) 
for expansion. (4) Peptide pools were pulsed on 
autologous APCs that served as a target in a coculture 
with sorted cells that grow in the microwell cultures. 
To minimize the assays, cells from 2 or 3 cultures 
were combined in the assay wells. (5a) Cultures that 
showed recognition against peptide pools were further 
expanded for future testing. (5b) Cells from Pt.4097 
coculture assay were labeled and reactive T cells were 
single-cell sorted into 96-well plates containing lysis 
buffer and PCR primers for TCR sequencing.
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https://doi.org/10.1172/jci.insight.122467DS1). We then used the frozen tumor digest as a source of TILs by 
FACS isolating the CD3+PD-1+ and/or CD3+CD134+ subset (Figure 2A). Cells (1.5 × 103) were sorted, diluted 
to 3 cells/well, and cultured in REP conditions. Three weeks later, 64 cultures, labeled W1–W64, grew (~13% 
growth efficiency) and were tested for reactivity against 104 25mer peptides grouped in 7 peptide pools (PP1 
through PP7; Supplemental Table 3). Eight cultures showed substantial reactivity against several peptide pools 
(Figure 2B); however, the observation that TILs from W59 and W60 showed recognition of multiple peptide 
pools suggested that there was some peptide cross contamination across some peptide pools.
The 8 reactive cultures were further expanded using the REP and retested against PP1 through PP6 
(Figure 2C). At this stage, the functional coculture assays showed that 5 cultures (W7, W8, W18, W60, 
and W62) recognized unique peptide pools. Interestingly, culture W8 showed specific IFN-γ secretion 
when tested against PP1 that was not detected in the first screen, which might be attributable to insuf-
ficient peptide presentation on the DCs due to a large number of  peptides tested in the first screen (30 
peptides were used in the first screen; Figure 2B).
Next, we sought to identify the neoantigens recognized by microwell TIL cultures. To this end, 
we performed T cell cocultures against DCs pulsed with individual peptides derived from the relevant 
Figure 2. Sorting strategy, functional screen assays, and identification of neoantigen-reactive TCRs in Pt.4078. (A) Gating strategy used in flow 
cytometry–based sort for CD3+PD-1+ and/or CD134+ TILs. (B–D) ELISPOT assays measuring IFN-γ secretion of microwell cultures upon coculture with 
target cells. (B) Following expansion, pools of 2 cultures were tested against autologous DCs pulsed with 2 peptide pools (PP), indicated by symbols.  
(C) Cultures from the reactive pools were tested separately against autologous DCs pulsed with all suspected peptide pools. (D) IFN-γ ELISPOT and 
CD137 flow cytometry analysis showing reactivity of the TIL cultures following coculture with autologous DCs pulsed with single 25mer peptides from 
each peptide pool. (E) Allogeneic T cells retrovirally transduced with neoantigen-reactive TCRs cocultured with autologous DCs pulsed with serially dilut-
ed mutated and WT 25mer peptides. ‘>’ denotes greater than 500 spots. All data are representative of at least 3 independent experiments except in A.
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peptide pools (Figure 2D). Both IFN-γ secretion and upregulation of  T cell activation markers assessed 
by flow cytometry demonstrated that each TIL culture was reactive solely against 1 potential neoan-
tigen. Also, by coculturing W18 with COS7 cells transfected with the predicted or control HLAs and 
pulsed with the predicted minimal epitope, we were able to determine the restriction of  the reactivity 
(HLA-A*30:01, Supplemental Figure 1B). At this point, we were able to sequence TCRα and TCRβ of  
the reactive cultures using 5′RACE rapid cDNA amplification, using TCRα- and TCRβ-specific prim-
ers, followed by Sanger sequencing. All 5 cultures displayed unique and clonal TCRs (Table 1). To 
verify that the sequences of  the α and β chain are indeed encoding for neoantigen-reactive TCRs, we 
first cloned the sequences into a retroviral vector (pMSGV1) and introduced the TCRs into allogeneic 
PBMCs, as described previously (13). Subsequently, coculture of  the TCR-gene-modified cells with 
autologous APCs pulsed with a serial dilution of  HPLC-grade mutated and counterpart WT peptides 
confirmed that the isolated TCRs were neoantigen reactive (Figure 2E).
To evaluate the sensitivity of  our new high-throughput approach we determined the frequencies 
of  the neoantigen-reactive TCRβ sequences in the tumor digest. For this purpose, we performed TCRβ 
deep sequencing of  the bulk tumor digest and 4 FACS-isolated subsets of  the tumor digest: CD4+PD-1+, 
CD4+PD-1–, CD8+PD-1+, and CD8+PD-1–. Frequencies of  the neoantigen-reactive TCRs in the bulk popu-
lation were extremely low, ranging from 0.026% to 0.0009% (Table 1), which may at least partially explain 
why no neoantigen reactivity was detected using the TIL fragment screen approach. Moreover, 4 out of  
the 5 TCRs were detected in the PD-1+ subsets and only one, W7, was detected in the PD-1– subset, sug-
gesting that it likely came from the PD-1–CD134+ population, which is consistent with our previous obser-
vations that sorting PD-1+ T cells from tumor digests enriches for tumor- and neoantigen-reactive T cells 
(13). Nevertheless, in some cases like culture W7, enrichment for PD-1+ alone is insufficient to isolate all 
neoantigen-reactive T cells. However, this could be overcome by using other T cell activation markers, 
such as CD134. In summary, we were able to detect T cell reactivities against 5 neoantigens that were not 
detected when multiple TIL fragments from the same lesion were tested. Moreover, we were able to isolate 
rare neoantigen-reactive TCRs.
To assess the reproducibility of our approach, we employed our new high-throughput multiwell culturing 
protocol to screen 5 additional metastatic tumor digest samples from cancer patients with various histologies. All 
subjects were previously screened using the tumor fragment screening approach, as part of the NCT01174121 
trial (Table 2 and Supplemental Table 1). Using our high-throughput multiwell culturing approach we were 
able to detect TIL reactivities in all 5 additional cases. In total, we were able to detect neoantigen reactivities 
against 19 different neoantigen targets as compared with 9 that were detected using TIL fragment screening 
(Table 2, Supplemental Table 2, and Supplemental Figures 2–5). In the new approach, CD4+ and CD8+ T 
cells targeting 18 and 1 neoantigens, respectively, were found, while 6 and 2 neoantigens recognized by CD4+ 
and CD8+ T cells, respectively, were detected using the standard TIL fragment screening method. Out of the 6 
neoantigen reactivities targeted by CD4+ T cells identified using the TIL fragment screening approach, 5 were 
identified in our new method. Overall, these results demonstrate the reproducibility and the high sensitivity of  
our new culturing and screening approach.
Table 1. TRBV sequences of neoantigen-reactive cultures and their frequency in tumor digest subsets
Culture CD4/CD8 Mutated gene CDR3β Frequency in tumor digest
Bulk PD-1+ PD-1–
W7 CD4 PLXNB3
TRBV6-1*01
0.011 ND 0.0373
CASNLQRAVNTEAF
W8 CD4 DLAT
TRBV2*01
ND 0.06 ND
CASTGANVLTF
W18 CD8 GBAS
TRBV2*01
0.0009 0.092 ND
CASSETGWGAF
W60 CD4 TMPRSS4
TRBV7-2*01
0.0078 0.98 ND
CASSSSGAFQPQHF
W62 CD4 PSMD2
TRBV25-1*01
0.026 1.68 ND
CASRGVGGGTEAF
ND, not detected.
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Rapid identification and sequencing of  neoantigen-reactive TIL TCRs. For metastatic cancer patients, the time 
to clinical intervention is critical. In our attempt to shorten the time of  isolation of  neoantigen-reactive TCRs, 
we utilized scPCR in our screening pipeline to detect reactive TILs, as previously described (15). To investi-
gate the feasibility of  incorporating this approach early in the microwell screens we studied cryopreserved cell 
digests of  a metastatic right groin lymph node from a patient with serous ovarian carcinoma (Pt.4097). Fol-
lowing the in vitro expansion of  microwell cultures containing CD3+PD-1+ and/or CD134+ cells, a functional 
assay was carried out, as described above (Figure 3A). Following the incubation coculture, we transferred the 
cells from the ELISPOT plate into new 96-well plates. After we developed the IFN-γ ELISPOT assay plates 
we stained the cells from coculture wells that showed enhanced IFN-γ secretion and sorted single T cells 
that upregulated T cell activation markers into 96-well PCR plates for TCR sequencing (Figure 3B). Several 
microwell TIL cultures showed recognition against PP15+16, while only 2 coculture wells showed recogni-
tion against DCs pulsed with PP1+2 or PP17+18, respectively. Similar to previous screens, for further study 
of  the reactivities against mutated peptides, putative TIL microwell cultures were further expanded for 2 
weeks. However, following the first coculture assay, we were able to obtain unique TCR sequences of  the reac-
tive wells with our scPCR method combined with Sanger sequencing (Figure 3C). Next, following expansion, 
we studied the reactivities of  the single TIL microwell cultures against APCs pulsed with single peptide pools 
and the individual peptides (Figure 3D). After we identified the neoantigens, we sequenced the TCRs of  the 
reactive cultures using TCRβ deep sequencing and confirmed the sequences that were obtained using scPCR. 
In summary, we were able to identify and sequence neoantigen-reactive TCRs 4 weeks after we seeded the 
microwell TIL cultures. This rapid and reliable approach could be valuable for our clinical trial seeking to 
improve the efficacy of  personalized cancer immunotherapy treatment with ACT using PBMCs genetically 
modified to express neoantigen-reactive TCRs.
Isolating TP53 hot-spot driver mutation–reactive TCRs. The overwhelming majority of  cancer-associated 
mutations are private and unique to the individual, which means that the targeted neoantigens expressed in 
Table 2. Summary of neoantigen reactivities found using the new approach compared with reactivities found in TIL fragments
Patient ID AgeA/Sex Tumor histology No. of mutations 
assessed
Reactivities 
found in TIL 
fragment screenB
T cell type Reactivities 
found in LD 
culturesB
T cell type No. of reactive 
TCRs found using 
LDC
4078 48/M Gastroesophageal 
junction 
adenocarcinoma
104 None GBASE207K CD8 1
PLXNB3W609G CD4 1
DLATG294L CD4 1
TMPRSS4H233Y CD4 1
PSMD2G644A CD4 1
4097 59/F Ovarian 317 HIST1H1BA71D CD4 HIST1H1BA71D CD4 7
INPP5KL176V CD4 HYAL4R94S CD4 1
HSPG2H3568L CD4 1
4148 68/F Endometrial 108 None KRASG12V CD4 1
4217 49/M Colon 176 MAP3K2S153F CD4 MAP3K2S153F CD4 1
UEVLD-1/2F191V CD4 UEVLD-1/2F191V CD4 3
RAD51BL202R CD4 RAD51BL202R CD4 3 (2 + 1)
MUC4R4435S CD8 TBCKR747S CD4 1
4127 58/F Ovarian 180 TP53G245S CD4 TP53G245S CD4 3
HIST1H2BME77V CD4 1
GORASPL248FS‡ CD4 3 (2 + 1)
TUBA1BS287T CD4 1
4166 40/M Pancreatic 156 NPLOC4I312V CD8 ZNF727H163Q CD4 1
TNCE743D CD4 4
Total: 8 CD8: 2 19 CD8: 1
CD4: 6 CD4: 18
AAt the time of admission. BNeoantigen specificity was determined by testing against WT peptides. CTCRs that were constructed and tested are bolded. 
‡FS, frame-shift mutation. LD, limiting dilution.
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one patient are not likely to be expressed in other patients. Moreover, due to intratumoral heterogeneity, pri-
vate mutations might be subclonal. On the other hand, public or shared hot-spot mutations are more likely 
to be expressed by all cells within a tumor as well as across tumor samples and histologies. Thus, ACT using 
off-the-shelf  TCRs targeting shared mutations when possible appears to be an additional attractive strategy 
to target cancer neoantigens.
To this end, we employed our approach to screen for neoantigen reactivities in Pt.4127, a metastatic ovar-
ian cancer patient whose tumor expressed a hot-spot mutation in the TP53 gene. In a previous study, CD4+ 
T cells reactive to the TP53G245S hot-spot mutation were detected when TIL fragments were tested against 
peptides and TMGs encoding patient’s nonsynonymous mutations, and 3 TCRs targeting this mutation were 
isolated from TIL fragments (26). Here, to screen for neoantigen-reactive TILs we utilized the sorting strategy 
that was described in Figure 1 and Figure 2A. We sorted 3,300 cells expressing CD3+PD-1+ and/or CD134+ 
(denoted with “O”), and 1,320 cells expressing CD3+PD-1+ and/or CD137+ (denoted with “B”) and cultured 
them at 3 cells/well in REP conditions. Three weeks later, growth efficiencies for CD3+PD-1+ and/or CD134+ 
and CD3+PD-1+ and/or CD137+ were 12% and 7%, respectively. In addition to identifying CD4+ T cells that 
recognized 3 patient-specific neoantigens that were not detected with the standard TIL fragment screening 
method (Supplemental Figure 2), our new culture method also detected multiple microcultures that recog-
nized the TP53G245S hot-spot mutation (Figure 4, A and B).
To further characterize the TP53G245S-reactive TCRs, we first sequenced the TCRs from cultures O37, 
O71, and O102, using 5′RACE. The α and β chains were subcloned into a retroviral plasmid and transduced 
into allogeneic donor PBMCs. To determine the HLA restriction of  the TCRs, we coincubated the TCR-
transduced PBMCs with COS7 cells transiently expressing the patient’s HLA class II molecules and pulsed 
with mutated TP53 peptide. Interestingly, the recognition of  all 3 TCRs was restricted to HLA-DRB3*02:02 
Figure 3. Rapid sequencing of neoantigen-reactive TCRs from Pt.4097. (A and B) Pools of TIL cultures incubated with DCs pulsed with pooled peptide 
pools (PP), indicated by symbols. (A) Summary of TIL culture pools showing secretion of IFN-γ in ELISPOT. (B) Cells from ELISPOT coculture wells were 
collected, labeled, and single cells expressing T cell activation markers were sorted (as shown in the bottom right panel) into a 96-well PCR plate contain-
ing lysis buffer and PCR primers for TCRα and -β. (C) CDR3β of the sequenced culture well. Bolded are the origin of the reactive TCR, based on functional 
assays done with the individual cultures (data not shown). (D) Expanded cultures from the indicated TIL microwells coincubated with autologous DCs 
pulsed with single peptides from the pools that the cultures showed recognition against in previous experiments, representative of at least 2 independent 
experiments. ‘>’ denotes greater than 500 spots.
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(Figure 4C), which is expressed in up to 33% of  White individuals in the US (www.allelefrequencies.net). 
Finally, to test the avidity of  recognition, we cocultured TCR-transduced cells with autologous DCs pulsed 
with a serial dilution of  mutated and WT peptides (Figure 4D). Although all 3 TCRs had higher avidity for 
the mutated peptide compared with the WT peptide, the TCR isolated from the O37 culture showed greater 
specificity against the mutated peptide compared with the other 2 TCRs. Due to the high allele frequency 
of  HLA-DRB3*02:02, the frequency of  the mutation (2.8% of  all tumors; see ref. 27), and high specificity 
of  the receptor, the TCR isolated from O37 might be attractive as an off-the-shelf  reagent that could be used 
in TCR-gene therapies for patients with metastatic cancer. Altogether, using our high-throughput method 
we were able to detect and isolate multiple TCRs from CD4+ cells targeting 4 neoantigens. Three of  these 
neoantigens were not detected when TIL fragments were tested.
Isolation of  a highly potent KRASG12V-targeting TCR. Encouraged by our ability to isolate TCRs target-
ing the TP53G245S hot-spot mutation and given that KRAS mutations, mainly at positions 12 and 13, are 
highly prevalent (28, 29), we sought to use our high-throughput culturing approach to identify neoantigen-
reactive T cells in tumors expressing KRAS driver mutations. For this purpose, we used cryopreserved 
tumor digest from Pt.4148 to prepare the microwell cultures. Pt.4148, a metastatic endometrial cancer 
patient, was enrolled in NCT01174121 and her tumor TIL fragments were screened for neoantigen reactivi-
ties. No reactivity was found against the peptide pools or against the KRASG12V 24mer, which was pulsed 
Figure 4. Isolation and characterization of 3 TP53G245S neoantigen-reactive TCRs from Pt.4127 sorted TIL microwell cultures. TILs from tumor digest 
were sorted and expanded based on the expression of PD-1 and/or CD134. (A) Cells from 2 cultures were combined and cocultured with DCs that were 
pulsed with pools of mutated peptides. Showing cultures displayed enhanced IFN-γ secretion against peptide pools 9 and 10 (pool 9 encompassing TP53 
mutated peptide) in (B) IFN-γ ELISPOT assay at 16 hours. Following expansion, 2 × 104 cells from individual TIL cultures that showed specific reactivity 
against peptide pool 9 (not shown) were cocultured with 1 × 105 DCs pulsed with single peptides present in the pool. (C and D) TCRs targeting TP53G245S 
were sequenced, synthesized, and virally delivered into allogeneic PBMCs to assess reactivity and specificity. (C) TCR-transduced cells were coincubated 
with COS7 cells that were transfected with plasmids encoding the patient’s HLA class II and pulsed with mutated 25mers. (D) Cells were coincubated 
with autologous DCs pulsed with serially diluted TP53G245S and WT peptides. ‘>’ denotes greater than 500 spots. All data are representative of at least 2 
independent experiments except in A.
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individually in the screen (data not shown). Therefore, we used our high-throughput screening method to 
test whether we could identify neoantigen-reactive T cells. We sorted 1,720 CD3+PD-1+ and/or CD134+ 
TIL cells, expanded them at 3 cells/well, and 76 cultures were screened 3 weeks later (~13.5% growth effi-
ciency) against 6 peptide pools (Supplemental Table 4). Only 1 microwell CD4+ culture, W7, demonstrated 
enhanced IFN-γ secretion when tested against peptide pools (Figure 5A). Deconvolution of  the peptides 
from PP1 showed PP1-17, a 24mer peptide encompassing the KRASG12V mutation, as the potential neoan-
tigen targeted by W7 (Figure 5B). The TCR from culture W7 TIL microwell culture was Sanger sequenced 
and revealed unique α and β chains that were subcloned into a retroviral expression plasmid and transduced 
into autologous PBMCs for further testing. Interestingly, the TCR sequence was present at a very low fre-
quency (0.056%) in the tumor digest and ranked 287 based on TCRβ deep sequencing.
In order to test the specificity of  the receptor, autologous DCs were liposomally transfected with RNA 
expressing full-length WT KRAS, KRASG12D, or KRASG12V, washed, and cocultured with transduced 
PBMCs expressing the receptor. Both cell surface upregulation of  CD137, assessed by flow cytometry, 
and IFN-γ secretion demonstrated high specificity of  KRASG12V recognition (Figure 5C). Since the TCR 
was isolated from CD4+ cells, the TCR more likely recognized a mutated protein that was presented by 
MHC II molecules expressed by APCs that had taken up the antigen from apoptotic cancer cells in the 
tumor microenvironment or draining lymph nodes. Thus, to test whether this TCR could recognize tumor 
lysates derived from KRASG12V-expressing cancer cells, we cocultured TCR-transduced cells with autolo-
gous DCs loaded with supernatant from cell lysates originating from mutated-KRAS-expressing cell lines 
(5:1 ratio of  DC/cell lines) including the TC4177, KRASG12V-expressing line established from a pancre-
atic lesion in our laboratory. KRASG12V TCR–transduced cells demonstrated specific recognition against 
autologous DCs loaded with lysates from KRASG12V-expressing cell lines but not KRASG12D, KRASG12C, 
Figure 5. Characterization of a highly potent HLA-DRB1*07:01–restricted TCR isolated from a metastatic lesion of endometrial cancer. CD3+PD-1+ and/
or CD134+ TILs were sorted, expanded at 3 cells/well, and cultures that grew were tested. (A) TIL microwell culture that showed recognition against DCs 
pulsed with pooled peptide pools (PP) were expanded and IFN-γ secretion was assessed following coculture for 16–20 hours with DCs pulsed with single 
peptide pools, and (B) single peptides from PP1. (C and D) The functionality of autologous PBMCs virally transduced with the TCR isolated from neoanti-
gen-reactive culture was measured following incubation with (C) DCs liposomally transfected with full-length RNA encoding for KRASWT, KRASG12V, and 
KRASG12D, and (D) DCs loaded with supernatant from lysed cell lines that underwent 5 cycles of freezing and thawing at 1:5:10 ratio (T cells/DCs/cell lines). 
(E) Autologous DCs pulsed with the mutated peptide were incubated with HLA-blocking antibodies for 2 hours prior to the addition of the PBMCs express-
ing the TCR. (F) Effector cells expressing the TCRs were incubated with DCs (pulsed with the mutated peptide) from donors matched at one of the DRB1 
alleles or with DCs from a complete DRB1 mismatch. ‘>’ denotes greater than 500 spots. All data are representative of at least 3 independent experiments.
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KRASG12R or WT, as demonstrated in Figure 5D. Furthermore, coincubation of  gene-engineered T cells 
expressing the receptors with autologous DCs pulsed with a serial dilution of  the 24mer peptide demon-
strated coreceptor-independent activation of  CD8+ cells (Supplemental Figure 3, C and D).
To determine which HLA allele presented the mutated KRASG12V epitope, we incubated autologous 
DCs loaded with KRASG12V peptides in the presence of  HLA-blocking antibodies and then performed 
cocultures with autologous peripheral blood lymphocytes (PBLs) transduced with the TCR. Although 
blocking HLA-II with anti–pan class II antibody slightly reduced CD137 expression, blocking HLA-DR 
showed a substantial reduction in IFN-γ secretion and CD137 cell-surface expression (Figure 5E). To 
determine the specific allele that presented the KRASG12V peptide, we pulsed the 24mer peptide on DCs 
from donors expressing either one of  the patient’s HLA-DRB1 alleles or donor DCs with complete allele 
mismatch; then, the DCs were washed and coincubated with TCR-transduced PBMCs. A specific T cell 
reactivity was seen when the TCR-transduced T cells were cocultured with the HLA-DRB1*07:01 donor 
(Figure 5E). To further test our results, and to test the possibility that KRAS-mutated peptide might be pre-
sented on HLA-DRB3–5 molecules, we pulsed the 24mer peptides on HEK293T-CIITA cells transfected 
with HLA-DRB1*07:01 and cocultured the cells with T cells expressing the TCR. Indeed, T cells were 
specific against the HLA-DRB1*07:01 (Supplemental Figure 3E). Further, to evaluate the potential of  this 
potent TCR to serve as an off-the-shelf  agent for cancer immunotherapy, we first assessed the expression 
frequencies of  KRASG12V and HLA-DRB1*07:01 in the US population. Based on the Allele Frequency Net 
Database (http://www.allelefrequencies.net) (30), in White and African Americans, 25%–30% and 12.6% 
of  the individuals express this allele, respectively. KRASG12V hot-spot driver mutations are expressed at high 
frequency in various histologies, approximately 22% of  pancreatic cancer patients (COSMIC database, 
http://cancer.sanger.ac.uk/cosmic); thus, given the frequencies of  HLA-DRB1*07:01 and G12V among 
cancer patients, this TCR would be a useful candidate for an off-the-shelf  cancer immunotherapy reagent. 
In summary, using our high-throughput sensitive approach, we were able to isolate a potent HLA class 
II–restricted TCR targeting the shared KRASG12V mutation.
Discussion
In this study, we describe a nonbiased, high-throughput approach to identify and isolate neoantigen-reac-
tive clones from tumor digests. Previous studies have shown that neoantigen-reactive CD4+ and CD8+ T 
cells can be detected in tumor lesions (4, 5, 14, 17, 31) and that reinfusion of  ex vivo expanded neoantigen-
reactive TILs can mediate tumor regression in metastatic cancer patients (4, 28, 32, 33). Although ACT of  
metastatic melanoma patients using unselected TILs achieved a 24% CR rate and 56% ORR (3), currently, 
the success in common epithelial cancers is limited. We have sought to improve the detection of  neoan-
tigen-reactive cells and shorten the time to identification of  reactive TCRs for possible use in autologous 
cell gene therapy. By employing our new high-throughput approach we identified T cell reactivities against 
14 new unique neoantigens that were missed when TIL fragments of  the patients were screened using our 
standard approach.
In previous studies, several methods have been developed to identify and isolate tumor- or neoantigen-
reactive TILs (12, 14, 15, 17–19, 31, 34). However, a number of  factors can limit their efficiency. The 
frequency of  neoantigen-reactive TILs can decline dramatically when cells are expanded ex vivo as a bulk 
culture, possibly due to overgrowth of  younger, nonreactive TILs at the expense of  exhausted reactive cells. 
Thus, reactive T cells present at low frequency in the excised tumor, as we showed in Pt.4078, Pt.4148, and 
Pt.4127, may be missed in conventional functional TIL screens using fragment cultures. Additionally, the 
antigen-experienced Temra cells, that have very low or no expression of  PD-1 (19, 22), might be missed in 
approaches that use the PD-1 as the sole marker for enrichment. Here, to overcome these obstacles we first 
FACS-isolated T cells expressing PD-1 and/or T cell activation markers from tumor digests and expanded 
them at low cell concentrations. The metastatic lesions studied in this work were excised from patients and 
tumor fragments were also cultured in high-dose IL-2 and tested against mutated peptides and TMGs, as 
previously described (5, 28, 33). The remainder of  the excised tumors were enzymatically digested and 
frozen for further testing described in this study.
We first tested our limiting-dilution approach on a tumor digest from Pt.4078. Our standard screening 
of  TIL fragments from Pt.4078 did not reveal reactivity against the pools of  the mutated 25mer peptides 
(Supplemental Figure 1A). However, when sorted TILs were cultured at 3 cells/well and expanded, 13% of  
the cultures grew and could be tested. To test all of  these cultures against peptide pools we had to minimize 
1 1insight.jci.org   https://doi.org/10.1172/jci.insight.122467
T E C H N I C A L  A D V A N C E
our screening assay to a manageable size by pooling 2 microwell cultures and testing against DCs pulsed 
with 2 peptide pools. As demonstrated in Figure 2B, the functional assays of  the mixed cultures showed 
enhanced IFN-γ secretion against several peptide pools. As a control, we tested bulk FACS-isolated cells 
using the same gating strategy (Figure 2A) and did not find reactivity against the pools. Five unique neo-
antigens were discovered when TILs were cocultured with DCs loaded with individual peptides (Figure 
2D), and Sanger sequencing revealed that all neoantigen-reactive cultures were clonal. To determine the 
frequency of  neoantigen-reactive T cells in the tumor we compared these TCR sequences to sequences of  
bulk, PD-1+, and PD-1– tumor-resident T cells. Interestingly, 4 TCRs were present in very low frequency 
in bulk T cells and 3 of  these 4 TCRs were enriched in PD-1+ sorted cells, although still found at low fre-
quencies (Table 1). The TCR sequence from culture W8 was present in PD-1+ only and not in the bulk nor 
PD-1–. Finally, the TCR from culture W7 was present in PD-1– and the unselected bulk population but not 
in PD-1+, suggesting that neoantigen-reactive T cells can be found in the PD-1–CD134+ population. These 
results are consistent with our previous findings that neoantigen-reactive T cells are enriched in PD-1+ T 
cells (18, 19). However, some cultures, such as W7, can be missed, suggesting that the additional markers 
used in our approach (CD134 or CD137) are able to improve the detection and isolation of  neoantigen-
reactive T cells. To summarize, our 2-step high-throughput approach allowed us to detect 5 T cell clones 
targeting 5 different neoantigens in this patient that were missed when TILs grown from tumor fragments 
were screened by our conventional method.
We presumed that starting microwell cultures with a low number of  antigen-experienced cells and fur-
ther expanding them, using an antibody stimulation, will drive them to a more senescent state. To test our 
assumption, we evaluated the expression of  differentiation and inhibitory markers in cells from 6 cultures 
of  3 patients. Five out of  6 cultures showed high expression of  LAG3 and TIM-3, consistent with our 
assumption (Supplemental Figure 6). We thus hypothesized that reactive TCRs introduced to autologous 
PBLs can be more advantageous than using expanded microwell cultures for adoptive cell transfer. Here, 
we showed that coupling a nested scPCR step with our screening step allowed us to isolate and sequence 
neoantigen-reactive TCRs quickly and efficiently.
Targeting driver oncogenes using off-the-shelf  therapeutic reagents is attractive since these mutations 
are likely to be homogeneously expressed in cancer cells across different cancer histologies (35). We recent-
ly showed that ACT using CD8+ TILs targeting the KRASG12D mutation led to a significant antitumor 
clinical response (4). Here, employing our approach on tumor samples from 2 patients enabled us to iden-
tify and isolate 4 TCRs targeting driver hot-spot mutations. Three TCRs were detected in a tumor sample 
from Pt.4127 targeting TP53G245S in the context of  HLA-DRB3*02:02 (Figure 4C). All 3 TCRs were spe-
cific against mutated TP53 peptide and not the WT counterpart. Since the frequency of  TP53G245S is 2.8% 
among all cancer patients and can be higher in several histologies (36), and the frequency of  individuals 
expressing the HLA-DRB3*02:02 is high (16.4% allele frequency in the White US population, http://
allelefrequencies.net), these TCRs are attractive candidates for off-the-shelf  cancer immunotherapy treat-
ments using autologous gene-engineered PBMCs.
Similar to TP53, mutations in KRAS are frequent and important for tumorigenesis of  many cancers. The 
hot-spot mutations in KRAS occur mainly at positions 12, 13, and 61 (28). In human cancers, KRAS muta-
tions have been identified in approximately 90% of  pancreatic ductal adenocarcinoma (PDAC) (37), and 
33% in colorectal cancer (COSMIC database, http://cancer.sanger.ac.uk/cosmic). In this study, we detected 
and isolated TCR from CD4+ TILs targeting KRASG12V. The G12V mutation is the second most frequent 
mutation among KRAS mutations (37%, 35%, 30%, and 24% in ovarian, prostate, pancreatic, and colorec-
tal, respectively [COSMIC database]) after KRASG12D. This TCR is a putative candidate to serve as an off-
the-shelf  therapeutic agent because of  its high specificity for the mutated but not the WT protein (Figure 
5C). Furthermore, to evaluate the potency of  the isolated TCR we incubated autologous DCs with super-
natant of  lysed cell lines expressing KRAS mutations followed by incubation with TCR-expressing PBLs. 
Although it is possible that tumor cells may express MHC class II on their surface, the predominant axis of  
class II–restricted peptide presentation in the tumor microenvironment likely remains APCs (38). The results 
of  this experiment, as presented in Figure 4D, in addition to the observation that the TCR can be triggered 
in a coreceptor-independent manner (Supplemental Figure 3C), demonstrate a high potency of  the TCR. 
Finally, we determined that the recognition is restricted by HLA-DRB1*07:01 using HLA-DRB1 matching 
donors (Figure 5E) and verified by HLA transfection into HEK293T-CIITA cells (Supplemental Figure 3D). 
The frequency of  individuals that have HLA-DRB1*07:01 is relatively high in the US (25%–30% and 12.6% 
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in White and African American, respectively). Thus, this TCR could be used as an off-the-shelf  reagent for 
TCR-gene therapy. In summary, our new high-throughput approach for sorting and culturing TILs enabled 
us to isolate a rare (present at 0.056% of  the rearranged TCRs in the tumor) and potent KRASG12V-targeting 
TCR from a tumor digest. This approach can complement the identification of  a KRAS-targeting receptor 
raised by immunizing HLA transgenic mice, as reported by other members of  our group (39). A previous 
study showed that TGB6F1 mice, which harbor the KRASG12R mutation in their germline, are prone to devel-
ope papilloma that progress to cancer, and immunization with the G12R peptide can generate specific CD4 
reactivities. Interestingly, the generation of  the G12R-specific CD4+ cells was correlated with enhancement 
of  tumor growth (40). However, since the mutation was encoded in the germline there is a possibility that the 
immunization generated CD4+ Treg cells that promoted the tumor growth.
Our findings showed enhanced detection of  neoantigen-reactive TILs. In 2 patients, Pt.4078 and Pt.4148, 
we isolated reactive cells that were present at a very low frequency in the tumor and were missed in TIL frag-
ment screens (Figures 2 and 5). In the tumor sample from Pt.4127, in addition to reactivity against TP53G245S 
that was found in TIL fragments we detected 3 additional neoantigen reactivities (Figure 4 and Table 2). In 
the remaining samples, although we found the same number of  neoantigen reactivities as found in TIL frag-
ments, the screen revealed several different neoantigens (Table 2). As mentioned earlier, only a small portion 
of  the tumor was used as a source of  TIL microwell cultures (while the bigger part was used to generate 
fragments [NCT01174121, protocol 10-C-0166]), we speculate that utilizing our approach on a bigger tumor 
sample may allow detecting additional reactivities. Furthermore, 2 of  the neoantigen reactivities that were 
detected by TIL fragment screening that were not detected in our method were CD8+ T cell epitopes. There 
are several possible reasons we are missing the reactivities: (a) high-dose IL-2 and OKT3 are not optimal for 
growing CD8+ TILs in microwell cultures in REP conditions, (b) due to the small number of  cells in tumor 
digests, in patients 4166 and 4217 we used CD134 alone in conjunction with PD-1 for cell isolation; however, 
several studies have reported that CD137 is a better marker for CD8 cells (41, 42), (c) CD4+ and CD8+ cells 
were not separated in the sort nor the culture and CD4+ cells may have overgrown in mixed cultures (3 cells/
well), and (d) in the first screen using our approach we pulse the cells with a large pool of  peptides in order 
to minimize the assay; this strategy can reduce the sensitivity of  the screen due to HLA peptide competition. 
To improve our approach we are planning to address these points by using larger tumor samples to generate 
tumor digests, separating CD4+ and CD8+ cells, using additional T cell activation markers for enrichment, 
and utilizing robotics in our pipeline to upgrade our high-throughput capacity.
In summary, we have developed a method that allows an enhanced and rapid identification of  neo-
antigen-reactive TCRs for personalized TCR-gene therapy as well as the identification of  TCRs targeting 
hot-spot neoantigens that may be used as off-the-shelf  reagents for TCR gene therapy.
Methods
Patients, tumor biopsies, and PBMCs. All samples were obtained from patients enrolled in NIH protocol 
10-C-0166 (NCT01174121) and after written, informed consent was granted. One or more metastat-
ic lesions were resected and was used for (a) whole-exome and RNA sequencing, (b) plating 24 TIL 
fragments for future screening and treatment as part of  the clinical protocol (11), and (c) the rest of  
the resected tumor was enzymatically digested followed by mechanical tissue separation, as previously 
described (19). Briefly, tumor specimens were minced under sterile conditions, followed by enzymatic 
digestion (RPMI-1640 with L-glutamine [Lonza]), 1 mg/ml collagenase IV (Sigma-Aldrich), 30 U/ml 
DNAse (Genentech), and antibiotics for several hours at 37°C and intermittent mechanical tissue separa-
tion using gentleMACS (Miltenyi Biotec). Tumor digests were then cryopreserved for further analysis. 
Leukapheresis was performed to obtain PBMCs.
Whole-exome and RNA sequencing. Genomic DNA purification, library construction, exome capture 
of  approximately 20,000 coding genes, next-generation sequencing of  fresh tumor embedded in opti-
mum cutting temperature (OCT, Sakura Finetek), and a matched normal leukapheresis sample were 
performed as previously described (43). An mRNA sequencing library was prepared from fresh tumors 
using the Illumina TruSeq RNA library prep kit. Putative nonsynonymous mutations were defined by 3 
or more exome variant reads, 7% or greater variant allele fraction (VAF) in the exome, and 10 or more 
reads in the matched normal sample. Putative mutations with a variant allele frequency of  greater than 
10% in the tumor exome, as well as mutations that were identified in both transcriptome and exome 
analyses, were initially selected for screening.
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T cell sorting and in vitro expansion. Cell sorting was carried out using the FACSJazz or FACSAria IIu 
instrument (BD Biosciences). Tumor digests were rested overnight at 37°C in complete 50/50 media (1:1 
mix of  RPMI-1640 with L-glutamine and AIMV [Gibco] supplemented with 100 U/ml penicillin, 100 μg/
ml streptomycin, 12.5 mM HEPES, and 5% human serum) in the absence of  cytokines. Bulk-sorted cells 
were gated on live (PI negative), single cells, CD3+PD-1+ and/or activation markers (CD134, CD137) as 
shown in Figure 1. Sorted cells were diluted and seeded in 96-well plates at 3 cells/well in REP media in 
the presence of  50 ng/ml OKT3 (Miltenyi Biotec), 3,000 IU/ml IL-2 (Aldesleukin, Chiron), and 1 × 105 
irradiated allogeneic feeder cells (Figure 1). On days 7 and 14, half  of  the medium was replaced with fresh 
50/50 medium containing IL-2. Microwell cultures were tested 3–4 weeks following the initial sort.
Antibodies for flow cytometry and blocking experiments. The following fluorescently conjugated antibod-
ies were purchased from BD Biosciences: CD3-PE/APC-H7/FITC (SK7), CD8-APC/PE-Cy7/PE (SK1), 
CD4-PE/FITC/BV421 (SK3), CD137-APC/PE (4B4-1), CD134-FITC/PE (ACT35), mTCRβ-FITC/PE 
(H57-597), CD14-PE (MφP9), CD80-PE (L307.4), and HLA-DR-PE-Cy7 (L243). Antibody PD-1-APC/
PE (MIH4) was from eBioscience. For HLA-blocking experiments we used pan-class II (clone IVA12), pan-
class I (clone W6/32), HLA-DR (clone HB55), HLA-DP (clone B7/21), and HLA-DQ (clone SPV-L3).
IFN-γ ELISPOT cocultures and flow cytometry assays to assess T cell activation. For peptide presentation, we 
used 5 × 104 to 1 × 105 cells/well of  autologous DCs as APCs. Crude peptides were used in the primary 
screens and HPLC-grade peptides were used in the late validation tests (GenScript). Briefly, DCs were 
pulsed overnight with 1–20 μg/ml peptides at 37°C in complete DC media composed of  RPMI contain-
ing 5% human serum, 100 U/ml penicillin and 100 μg/ml streptomycin, 2 mM L-glutamine, 800 IU/ml 
GM-CSF (Leukine), and 200 U/ml IL-4 (Peprotech). Subsequently, DCs were washed and coincubated 
overnight with 2 × 104 T cells in antibody-precoated ELISPOT plates.
For IFN-γ ELISPOT assays, ELIIP plates (Millipore, MAIPSWU) were pretreated with 50 μl of  70% 
ethanol per well, washed 3 times with PBS, and then coated with 50 μl of  10 μg/ml IFN-γ capture antibody 
(Mabtech, clone 1-D1K) and incubated overnight at 4°C. For OKT3 controls, wells were coated with a 
mixture of  IFN-γ capture antibody and OKT3 (1 μg/ml). For the PMA/ionomycin control we added 1:500 
diluted Cell Stimulation Cocktail (eBioscience, 00-4970-03) to T cell cultures. Prior to coculture, the plates 
were washed 3 times with PBS, followed by blocking with 50/50 media for 2 hours at room temperature. 
After 16–20 hours of  coculture, cells were harvested from the ELISPOT plates into a standard 96-well 
round-bottom plate for flow cytometry analysis, and then the ELISPOT plates were washed 5 times with 
PBS plus 0.05% Tween 20 (PBS-T), and incubated for 2 hours at room temperature with 100 μl/well of  
a 0.22-μm-filtered 1 μg/ml biotinylated anti–human IFN-γ detection antibody solution (Mabtech, clone 
7-B6-1, diluted in 1× PBS supplemented with 0.5% FBS). The plate was then washed 3 times with PBS-
T, followed by a 1-hour incubation with 100 μl/well of  streptavidin-ALP (Mabtech, diluted 1:3,000 with 
above diluent). The plate was then washed 5 times with plain PBS followed by development with 100 μl/
well of  0.45-μm-filtered BCIP/NBT substrate solution (KPL, Inc.). The reaction was stopped by rinsing 
thoroughly with tap water. ELISPOT plates were scanned and counted using an ImmunoSpot plate reader 
and associated software (Cellular Technologies Limited, Ltd). Expression of  the T cell activation markers 
CD134 and CD137 was assessed by flow cytometry at approximately 18–24 hours after stimulation. Briefly, 
cells that were harvested from the ELISPOT plate were pelleted, washed with FACS buffer (1× PBS supple-
mented with 1% FBS and 2 mM EDTA), and then stained with the appropriate antibodies for 30 minutes, 
at 4°C in the dark. Cells were washed with FACS buffer prior to acquisition on a BD FACSCanto I, BD 
FACSCantoII, and BD LSRFortessa flow cytometers. All data were gated on live (PI negative), single cells. 
Data analysis was carried out using FlowJo software (Tree Star).
Generation of  autologous APCs. Monocyte-derived, immature DCs were generated from PBMCs using 
the plastic adherence method, as previously described (5). Briefly, apheresis samples were thawed, washed, 
set to 5 × 106 to 10 × 106 cells/ml with neat AIM-V media (Life Technologies) and then incubated at 
approximately 1 × 106 cells/cm2 in an appropriately sized tissue culture flask and incubated at 37°C, 5% 
CO2. After 90 minutes, nonadherent cells were collected, and the flasks were vigorously washed with AIM-
V media, and then incubated with AIM-V media for another 60 minutes. The flasks were then vigorously 
washed again with AIM-V media and then the adherent cells were incubated with DC media. On day 4 or 
5, DCs were collected and used or frozen for future use.
HLA blocking and HLA restriction mapping. In antibody-blocking experiments, we preincubated target 
cells with 20–50 μg/ml blocking antibodies for 2–3 hours at 37°C, followed by coculture with effector 
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T cells. 16–22 hours later, supernatants were harvested and IFN-γ secretion was analyzed by ELISA. 
Cells were collected, labeled, and analyzed by flow cytometry. HLA restrictions were determined by 
transfecting COS7 or HEK293T-CIITA cell lines with pCDNA3.1 plasmids encoding the individual 
HLAs of  interest. The next day, cells were washed and pulsed with mutated peptide for 2–4 hours. 
Subsequently, peptides were washed and effector T cells were added. IFN-γ secretion was assessed 
by ELISPOT or quantified by ELISA. At the end of  the coculture, cells were collected, labeled, and 
expression of  CD134 and CD137 was assessed by flow cytometry.
TCR sequencing. For 5′RACE-based amplification, T cells were pelleted from TIL microwell cultures 
and total RNA isolated (RNeasy Mini kit, Qiagen). Total RNA then underwent 5′RACE as directed by 
the manufacturer (SMARTer RACE cDNA amplification kit, Clontech) using TCRα and -β chain constant 
primers. The sequences of  the α and β chain constant chain primers are: α, 5′-GCCACAGCACTGTT-
GCTCTTGAAGTCC; β, 5′-CAGGCAGTATCTGGAGTCATTGAG. PCR products were then isolated 
by standard agarose gel electrophoresis and gel extraction (Clontech). Products were then either directly 
sequenced or TOPO-TA subcloned followed by Sanger sequencing of  individual colonies (Macrogen).
scPCR for TCR sequencing was performed as previously described (31). Briefly, single-cell sorting was 
performed using a modified FACSAria IIu instrument based on T cell activation markers following cocul-
ture. Cells were sorted into reverse transcription PCR (RT-PCR) buffer and a series of  2 nested PCRs 
were done to amplify TCRα and -β chains. The first RT and amplification reaction was performed with 
a One-Step RT-PCR kit (Thermo Fisher Scientific) using multiplex PCR with multiple Vα and Vβ region 
primers and one primer for Cα and Cβ regions each. The RT-PCR reaction was performed according to 
the manufacturer’s instructions using the following cycling conditions: 50°C, 15 minutes; 95°C, 2 minutes; 
95°C, 15 seconds, 60°C, 4 minutes × 18 cycles; 4°C. For the second amplification reaction, 3 μl from the 
first RT-PCR was used as a template in total 25 μl PCR mix using HotStarTaq DNA polymerase (Qiagen) 
and multiple internally nested Vα and Vβ region primers and 1 internally nested primer for Cα and Cβ 
regions each (final concentration of  each primer was 0.6 μM). The cycling conditions were 95°C, 15 min-
utes; 94°C, 30 seconds, 50°C, 30 seconds, 72°C, 1 minute × 50 cycles; 72°C, 10 minutes; 4 °C. The PCR 
products were purified and sequenced by the Sanger method with internally nested Cα and Cβ region prim-
ers by GenScript.
TCR-Vβ deep sequencing was performed by immunoSEQ (Adaptive Biotechnologies) on genomic 
DNA isolated from TIL microwell cultures or frozen tumor.
TCR construction and viral transduction. Construction of  the TCRs was done by fusing the V-D-J of  the 
Vβ regions to the mouse TCRβ constant chain, and the TCRα V-J regions to the mouse TCRα constant 
chains. The chains were separated by a furin-SGSG-P2A linker. The chains were then synthesized and 
subcloned into the pMSGV1 retroviral vector (GenScript).
Viral transduction was performed as described previously (5). Briefly, 2 days prior to transduction 
PBMCs were cultured and stimulated in 24-well plates at 2 × 106 cells/well in 50/50 media in the presence 
of  300 IU/ml IL-2 and 50 ng/ml OKT3. To generate transient retroviral supernatants, pMSGV1 encoding 
the TCRs (2 μg/well) and the envelope-encoding plasmid pRD114 (1.4 μg/well) were cotransfected using 
Lipofectamine 2000 (Life Technologies) into the retroviral packaging cell line HEK293GP (1 × 106 cells per 
well of  6-well poly-D-lysine–coated plates, plated the day prior to transfection in the absence of  antibiot-
ics). Retroviral supernatants were collected at 48 hours after transfection, diluted 1:1 with DMEM media, 
and then centrifuged onto Retronectin-coated (10 μg/ml, Takara), non–tissue culture–treated 6-well plates 
at 2,000 g for 2 hours at 32°C. Activated T cells (2 × 106 cells/well, at 0.5 × 106 cells/ml in IL-2–containing 
T cell media) were then spun onto the retrovirus plates for 10 minutes at 300 g (low acceleration and brake). 
Activated T cells were transduced overnight, removed from the plates, and further cultured in 50/50 media 
containing 300 IU/ml IL-2. GFP and mock-transduction controls were included in transduction experi-
ments. Cells were typically assayed 10–14 days after retroviral transduction.
Study approval. All patient samples were obtained in the course of  a National Cancer Institute Institu-
tional Review Board–approved clinical trial, and patients provided informed consent.
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